We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Achillion Pharmaceuticals Inc | NASDAQ:ACHN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.76 | 6.93 | 6.75 | 0 | 01:00:00 |
Achillion Pharmaceuticals, Inc.
|
(Name of Issuer)
|
Common Stock, par value $0.001 per share
|
(Title of Class of Securities)
|
00448Q201
|
(CUSIP Number)
|
December 31, 2019
|
(Date of Event Which Requires Filing of this Statement)
|
|
☑ |
Rule 13d-1(b)
|
|
☐ |
Rule 13d-1(c)
|
|
☐ |
Rule 13d-1(d)
|
* |
The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.
|
(1)
|
The percentage reported is based on 140,046,647 shares of Common Stock, par value $0.001 per share outstanding as of 11/1/19.
|
Item 1(a). |
Name of Issuer:
|
Item 1(b). |
Address of Issuer's Principal Executive Offices:
|
Item 2(a). |
Name of Person Filing:
|
Item 2(b). |
Address of Principal Business Office, or if None, Residence:
|
Item 2(c). |
Citizenship:
|
Item 2(d). |
Title of Class of Securities:
|
Item 2(e). |
CUSIP Number: 00448Q201
|
Item 3. |
If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
|
(a)
|
☐
|
Broker or dealer registered under Section 15 of the Exchange Act.
|
(b)
|
☐
|
Bank as defined in Section 3(a)(6) of the Exchange Act.
|
(c)
|
☐
|
Insurance company as defined in Section 3(a)(19) of the Exchange Act.
|
(d)
|
☐ |
Investment company registered under Section 8 of the Investment Company Act.
|
(e)
|
☑
|
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
|
(f)
|
☐ |
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
|
(g)
|
☐ |
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
|
(h)
|
☐ |
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
|
(i)
|
☐ |
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
|
(j)
|
☐ |
Group, in accordance with
|
Item 4. |
Ownership.
|
|
(a) |
Amount beneficially owned: 7,511,700
|
|
(b) |
Percent of class: 5.36%
|
|
(c) |
Number of shares as to which such person has:
|
|
(i) |
Sole power to vote or to direct the vote
|
|
(ii) |
Shared power to vote or to direct the vote
|
|
(iii) |
Sole power to dispose or to direct the disposition of
|
|
(iv) |
Shared power to dispose or to direct the disposition of
|
Item 5. |
Ownership of Five Percent or Less of a Class.
|
Item 6. |
Ownership of More Than Five Percent on Behalf of Another Person.
|
Item 7. |
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
|
Item 8. |
Identification and Classification of Members of the Group.
|
Item 9. |
Notice of Dissolution of Group.
|
Item 10. |
Certifications.
|
February 14, 2020
|
|
(Date)
|
|
(Signature)
|
|
Neal Nenadovic/Chief Financial Officer
|
|
(Name/Title)
|
1 Year Achillion Pharmaceuticals Chart |
1 Month Achillion Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions